All News
Filter News
Found 74 articles
-
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences in September 2022
8/29/2022
Ventyx Biosciences, Inc. announced that Company executives will host investor meetings and provide a company overview during fireside chats at the following upcoming investor conferences:
-
Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958
8/15/2022
Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), today announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX958, a novel and selective allosteric TYK2 inhibitor.
-
Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
8/15/2022
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), today announced financial results for the second quarter ended June 30, 2022 and highlighted recent pipeline and business progress.
-
Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022
8/11/2022
Ventyx Biosciences, Inc. announced that it will report topline results from the Phase 1 trial of its selective, allosteric TYK2 inhibitor VTX958 as well as financial results for the second quarter ended June 30, 2022, after market close on August 15, 2022.
-
Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors
7/19/2022
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of Jörn Drappa, MD, PhD, to its Board of Directors.
-
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735
6/29/2022
Ventyx Biosciences, Inc. today announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX2735, a peripheral NLRP3 inhibitor, and the first of two product candidates from its NLRP3 portfolio.
-
Ventyx Biosciences to Participate in the Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Ventyx Biosciences, Inc. announced that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview during a fireside chat at the Jefferies Healthcare Conference being held June 8-10, 2022.
-
Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
5/12/2022
Ventyx Biosciences, Inc. announced financial results for the first quarter ended March 31, 2022 and highlighted recent pipeline and business progress.
-
Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer
5/9/2022
Ventyx Biosciences, Inc. announced the appointment of William Sandborn, MD, as President and Chief Medical Officer.
-
Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022
5/5/2022
Ventyx Biosciences, Inc. announced that it will report financial results for the first quarter ended March 31, 2022 after market close on May 12, 2022.
-
Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress
3/23/2022
Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced financial results for the full year ended December 31, 2021 and highlighted recent pipeline and business progress.
-
BioSpace Movers & Shakers, March 11
3/11/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers -
Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference
3/7/2022
Ventyx Biosciences, Inc. announced that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the Barclays Global Healthcare Conference being held March 15-17, 2022.
-
ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.
-
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
1/20/2022
ImmPACT Bio USA, Inc., a clinical-stage company developing transformative logic-gate based chimeric antigen receptor T-cell therapies for treating cancer, announced it has closed $111 million in Series B financing, led by venBio Partners along with co-leads Foresite Capital and Decheng Capital.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis
12/6/2021
Ventyx Biosciences, Inc. announced today that the first patient has been dosed in a Phase 2 randomized, placebo-controlled trial of VTX002 for the treatment of moderate-to-severe ulcerative colitis (UC).
-
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
11/19/2021
Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the following upcoming investor conferences.
-
Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update
11/17/2021
Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, today announced financial results for the quarter ended September 30, 2021.